RECEIVED **CENTRAL FAX CENTER**

NOV. 29. 2005 2:02PM

AVENTIS US PAT DEPT

NOV 2 9 2005

NO. 0075

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

SHAMEEM, Golam M.

David M. FINK, et al.

Art Unit:

1626

Application No.:

10/088,250

Filed:

December 23, 2002

Ø

Title: THIENOSOXAZOLYL-AND

THENYLPYRRAZOLYL PHENOXY

SUBSTITUTED PROPYL

DERIVATIVES USEFULE AS D4

ANTAGONISTS

hereby certify that this correspondence is be eposited with the United States Postal Service as I Mail in an envelope addressed to etents, P.O. Box 1450, Alexandri

November 29, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in \$1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under 1.114, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

	(p)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
-		1:97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed with an asterisk on the attached PTO-1449 (modified) have been previously submitted by the examiner or the applicant in related applications of this series: 10/088.369

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. HMR2023 US PCT

Please type a plus sign (+) inside this box \Rightarrow 🗸

Under the Panetwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0851-0031
Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute	for form 1449A/	PTO		Complete if Known			
INITO		N DIGG	I OBLIDE	Application Number	10/088,250		
			LOSURE	Filing Date	December 23, 2002		
STAT	rement	BY AP	PLICANT	First Named Inventor	FINK, et al.		
				Group Art Unit	1626		
((use as many s	heets as ne	cessary)	Examiner Name	SHAMEEM, Golam M		
Sheet	1	of	2	Altomey Docket Number	USHMR2023 - US - PCT		

				U.S. PATENT DOCL	MENTS	_
Examiner Initiats	Cita No.1	U.S. Paten Number	Kind Code ² (# 1010mm)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Uncs, Where Relevant Passages or Relevant Figures Appear
	•	5,256,672		WETTLAUFER, et, al.	10-26-1993	
	٠	5,576,319		BAKER, et. al.	11-19-1998	
	•	5,780,474		PEGLION, et al.	07-14-1998	
	•	5,114,936		WETTLAUFER, et, al.	05-19-1992	
	•	5,143,923		HRIB, et. al.	09-01-1992	
	,	5,177,088		EFFLAND, et. al.	01-05-1983	
	•	5,180,834		WETTLAUFER, et, al.	01-19-1993	
	•	5,225,412		HRIB, et. al.	07-06-1993	
		5,328,920		EFFLAND, et. al.	07-12-1994	
	•	6,022,880		EFFLAND, et al.	02-08-2000	
					1	
•						**
			4			· · · · · · · · · · · · · · · · · · ·

			FOR	EIGN PATENT DOCUMENT	rs		
Cite No.1	Office		Cument Kind Code ⁵ (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
7	JP	10095770		MASANORI, et. al.	04-14-1998		
•	wo	92/08718		HOWARD, et. al.	05-29-1992		
•	wo	97/23482		SANNER, et. al.	07-03-1997		
•	WO	97/40027		LEYSEN, et. al.	10-30-1997		
•	wo	99/40067		DEN HARTOG, et al.	08-12-1999		
							+
		 _					╀┤
		No.¹ Office - JP - WO - WO - WO	Cits No.1 Offices Number4 7 JP 10095770 8 WO 92/08718 7 WO 97/23482 9 WO 97/40027	Foreign Patent Document	Foreign Patent Document Name of Patentse or Applicant of Cited Document	Cite No.1 Office3 Number4 Kind Code5 Applicant of Cited Document MM-DD-YYYY	Name of Patentee or Date of Publication of Pages, Columns, Lines, Where Relevant Passages or Relevant Pa

Examiner	Date	
Signature	Considered	
		L

¹ Unique citation designation number. 2 See ettached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). A For Japanese patent documents, the indication of the yeer of the reign of the Emperor must procede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not officion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet

2

Substitute for form 1449B/PTO

2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

PTO/SB/08B (10-95)

Approved for use through 10/31/99. OMB 0531-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no parsons are required to respond to a collection of information unless it contains a valid QMB control number.

Co	Complete if Known			
Application Number	10/088,250			
Filing Date	December 23, 2002			
First Named Inventor	FINK, et al.			
Group Art Unit	1626			
Examiner Name	SHAMEEM, Golam M			
Altomey Docket Number	USHMB2023 - US - PCT			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initals	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litem (book, magazine, journal, serial, symposium, catalog, etc.), data, page(a), volume-issue number(e), publisher, city and/or country where published.						
	*	KONGSAMUT, S., et. al., lloperidone Binding to Human and Rat Dopamine and 5-HT Receptors, Database Chemabs online! Chemical Abstracts Service, Columbus, Ohio, US retrieved from STN Database Accession No. 126:70003 XP002154323 * Eur. J. Pharmacol. (1996) Vol.317, (2/3)						
Examiner	T	Date						
Signature		Considered						

^{*}EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation Is attached.